Materialise: Defense Stops Being a Footnote

Series production is compounding at 30%, net cash is a fifth of the equity — and software still hasn't shown up for the series-manufacturing era.

MTLS · Earnings Call · 2026-10-28

The Footnote That Became a Driver

A year ago on this very call, Brigitte de Vet-Veithen was asked about defense and answered plainly: “the defense area at this point in time is not a significant market for us yet.” — Brigitte de Vet-Veithen, Chief Executive Officer · 2025-10-28 Last quarter she noted budgets were being freed up. This quarter defense is one of three named engines behind the best line in the release: “revenues for series production growing by more than 30% year-over-year in the quarter, driven by demand from the aerospace, semiconductor, and defense industries.” — Brigitte de Vet-Veithen, Chief Executive Officer · 2026-10-28 That is the series production pivot finally arriving in numbers rather than in slideware. The headline manufacturing decline — revenue down 6% to €21.3 million — is an artifact of recent divestitures; strip out RapidFit and Eyewear and the segment grew 1.5% while consolidated revenue rose nearly 5%. Segment adjusted EBITDA improved to a loss of €0.3 million from €0.8 million. Note the sequencing: in February management told investors manufacturing EBITDA would turn positive this year. It hasn't yet, with one quarter to go. The most striking piece of new business is not commercial at all. Materialise signed with the Superhumans Center in Ukraine to supply patient-specific craniomaxillofacial reconstructive solutions for war injuries, plus software access and surgical training in Kyiv and Lviv. That is adoption of personalization with a geopolitical tailwind — and a template for selling surgical planning into under-built health systems rather than into the capital budgets of U.S. academic centres.

Software: The Long Conversion

Software fell 4% to €9.9 million with a 15% adjusted EBITDA margin. Management blamed cautious customer spending and extended sales cycles. Here is the tension: those exact phrases have anchored the software narrative for three consecutive quarters. This is not a new explanation, it is an old one maturing. Analyst Troy Jensen pushed precisely where the story is weakest:

I always thought that your software would benefit as production applications start to increase. You need fewer software packages, right, with prototyping, and it seems like production is increasing, but you're still kind of talking about some tough spending environments here. So thoughts on, is it competitive? More competition in the space? Or other thoughts on the stagnant software business?
Troy Jensen, Analyst · 2026-10-28

The answer is the most useful thing said on the call: “when it comes to supporting series manufacturing in the market with our CO-AM product, it is a sales process where there is a lot more involvement of teams from both sides... So the extended sales cycles that we are now feeling as we focus more and more on series production” — Brigitte de Vet-Veithen, Chief Executive Officer · 2026-10-28. In other words the CO AM platform sells to a different buyer, on a qualification timetable measured in quarters, while the fast-selling prototyping tools it replaced are shrinking. The segment is wedged between two business models, and the good news buried in it is that recurring revenue is now 84% of software and management says the mix has stabilised — the perpetual-to-subscription drain is over. Whatever recovery comes next drops through to margin.

Cash Is the Story

Net cash rose to €82.5 million, up almost €12 million from the start of the year, against €153.5 million of cash and €71 million of gross debt after the final €15 million drawdown of a committed facility. Year-to-date free cash flow of €22.8 million is more than double last year. The company bought back €7.5 million of stock, close to 1.5 million ADSs, or 2.4% of the share base. Against a roughly $397 million market capitalisation, net cash is about a fifth of the equity. cash generation is the top-ranked keyword in this quarter's set, and for once the ranking is earned rather than reflexive. But the balance sheet carries an unanswered question. Drawing the last debt tranche while holding €153.5 million of cash only makes sense as dry powder. On the July 2025 call, Koen Berges said the facility was “targeted at being used for CapEx or M&A investments in the future” — Koen Berges, Chief Financial Officer · 2025-07-24. Fifteen months later the facility is fully drawn and no acquisition has been announced. Meanwhile the fourth quarter carries the year: nine-month revenue of roughly €204 million against reaffirmed guidance of €273-283 million implies a Q4 near €74 million, and nine-month adjusted EBIT of €8.8 million against a €12-14 million target requires the best quarter of the year. Q4 is seasonally the strongest for the medical business, so it is achievable — but it is a real ask.

What This Is Not

The market's own curated leaderboard this quarter is a wall of AI data center, memory pricing, Fed rates and tariff noise. Materialise shares essentially none of it. Its nearest adjacency is semiconductors, and even there it is a parts supplier into process control-type equipment, not a direct read on hyperscaler capex. What it actually sells is European rearmament, aerospace qualification cycles, hospital capital budgets and advanced 3D planning. Equally telling is what vanished from the script. In February, the weak European industrial climate was expected to weigh on manufacturing “in particular on the prototyping segment” — Brigitte de Vet-Veithen, Chief Executive Officer · 2026-02-19. This quarter the same geography re-enters as a growth story: “Building on the foundations that we had built traditionally in the automotive sector, we are still seeing a large part of our revenue coming from what we call the broader transportation sector.” — Brigitte de Vet-Veithen, Chief Executive Officer · 2026-10-28 And the U.S. academic funding cuts that carried a keyword slot in the first quarter have quietly exited the narrative, as has most of the automotive gloom. Prototyping is still soft — that has not been fixed — but the framing has flipped. The re-rating case writes itself: if series production keeps compounding near 30% and the software base stops shrinking, a company with a fifth of its market cap in net cash and €12-14 million of EBIT is not expensively valued. The risk is timing. The CO-AM conversion has been one or two quarters away for three quarters now, and the market is currently paying for a different kind of company entirely.